-transparent.png){kind=logo}
Recombinant adenoviruses carrying the hepatitis B virus surface antigen coding sequence in the adenovirus E3 region were constructed using DNA from either adenovirus type 5 or an adenovirus type 5 E3-region deletion mutant. Both of these recombinant adenoviruses replicated as efficiently as wild-type adenovirus in all human cells tested, including the human diploid cell strain WI-38. This indicates that insertion of the hepatitis B virus surface antigen gene into the E3 region does not significantly affect viral replication. Human cells infected with these recombinant adenoviruses secreted immunoreactive hepatitis B virus surface antigen. Since a practical small animal model for human adenoviruses was lacking, a hamster model was developed to evaluate the immunogenic potential of these recombinant adenoviruses. Upon intranasal inoculation, both wild-type adenovirus and the adenovirus E3-region deletion mutant replicated in the lungs of these animals and induced an antibody response against adenovirus. Hamsters similarly immunized with the live recombinant adenoviruses produced antibody against both adenovirus and hepatitis B virus surface antigen.
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
August 1991,
The Journal of general virology,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
November 1985,
Proceedings of the National Academy of Sciences of the United States of America,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
January 1985,
Transfusion,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
May 1984,
The New England journal of medicine,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
August 1985,
Annals of internal medicine,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
December 1996,
The Journal of infectious diseases,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
May 2012,
Cancer biotherapy & radiopharmaceuticals,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
August 1987,
American journal of clinical pathology,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
January 2006,
Human vaccines,
J E Morin, and
M D Lubeck, and
J E Barton, and
A J Conley, and
A R Davis, and
P P Hung
September 2009,
Journal of medical virology,
